<DOC>
	<DOCNO>NCT00888693</DOCNO>
	<brief_summary>Evaluate safety , tolerability pharmacokinetics ABT-288 order determine maximum tolerate dose ABT-288 stable schizophrenic volunteer receive treatment atypical antipsychotic .</brief_summary>
	<brief_title>A Multiple Dose Study Safety , Tolerability , Pharmacokinetics , Pharmacodynamics ABT-288 Stable Subjects With Schizophrenia</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<criteria>Subject sign informed consent ; Current DSMIVTR diagnosis schizophrenia ; Clinically stable single secondgeneration antipsychotic past 8 week ; Meets studyspecific PANSS criterion ; Willing able cooperate cognitive testing Females pregnant , breastfeeding ; Females postmenopausal surgically sterile practice birth control ; Males surgically sterile agree sexually inactive use barrier method birth control Subject substance dependence disorder sustain remission least 1 year ; Diagnosis schizoaffective disorder ; Bipolar disorder , manic episode , dementia , OCD , druginduced psychosis current major depressive disorder ; Diagnoses mental retardation ; acute psychosis hospitalization within past 6 month ; Current clozapine treatment ; suicidal ideation behavior ; BMI 39 great ; current homicidal violent ideation ; Medical CNS condition schizophrenia could affect cognitive performance testing ; relevant drug sensitivity allergy ; positive urine screen alcohol drug abuse ; Positive hepatitis HIV test result ; Recent clinically significant illness/infection surgery ; Recent blood product transfusion , donation loss 5 mL/kg blood ; Visual , hear communication disability</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>October 2010</verification_date>
</DOC>